adam15  (R&D Systems)

Journal: Cell reports

Article Title: PAI-1-Dependent Inactivation of SMAD4-Modulated Junction and Adhesion Complex in Obese Endometrial Cancer

doi: 10.1016/j.celrep.2020.108253

Figure Lengend Snippet: (A–C) Expression profiles of SMAD4 and JAC based on CyTOF were classified into five categories: I, II, III, IV, and V. Violin plots show ordered SMAD4 expression level (low to high) and distribution in the individual subpopulations (A). Expression heatmaps of JAC were aligned according to SMAD4 expression levels (in descending order) in different cellular subpopulations (B). Area of circle denotes relative cell proportion of a subpopulation within each sample and ordered in the aforementioned five categories in cellular subpopulations of EME6/7t lines and primary tumors (C). Tumors were ordered from top to bottom based on increased patients’ BMIs and histology classes. (D) Balloon plots of subpopulation distributions of endometrial tumors in the five categories based on histology and BMI. Circle area indicates the size of each subpopulation. Categories IV and V were associated with relatively high expression levels of SMAD4 and JAC, whereas low levels of SMAD4 and JAC were noted in categories I, II, and III. (E) Violin plots showing the average expression levels of four JAC markers—ADAM15, ROCK1, Cx43, and Gas1—based on patients’ tumor histology: papillary serous and endometrioid. (F) Balloon plots of subpopulation distributions in the five categories stratified by BMI into three groups: normal weight (NW), obesity (OB), and morbid obesity (MOB). (G) Violin plots showing the average expression levels of ADAM15, ROCK1, Cx43, and Gas1, based on three BMI groups: NW, OB, and MOB. Lower JAC expressions corresponded with patients with higher BMIs. ****p < 0.0001. See also .

Article Snippet: ADAM15 (clone 23G9) , Novus Biologicals , Cat# MAB935-100.

Techniques: Expressing

Journal: Cell reports

Article Title: PAI-1-Dependent Inactivation of SMAD4-Modulated Junction and Adhesion Complex in Obese Endometrial Cancer

doi: 10.1016/j.celrep.2020.108253

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: ADAM15 (clone 23G9) , Novus Biologicals , Cat# MAB935-100.

Techniques: Ubiquitin Proteomics, Recombinant, Multiplex Assay, Reverse Transcription, SYBR Green Assay, In Situ, shRNA, Software

Journal: Cell reports

Article Title: PAI-1-Dependent Inactivation of SMAD4-Modulated Junction and Adhesion Complex in Obese Endometrial Cancer

doi: 10.1016/j.celrep.2020.108253

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: ADAM15 (clone 23G9) , Novus Biologicals , Cat# MAB935-100.

Techniques: Ubiquitin Proteomics, Recombinant, Multiplex Assay, Reverse Transcription, SYBR Green Assay, In Situ, shRNA, Software

Journal: PLoS ONE

Article Title: MicroRNA-147b Regulates Vascular Endothelial Barrier Function by Targeting ADAM15 Expression

doi: 10.1371/journal.pone.0110286

Figure Lengend Snippet: (A) Schematic illustration of ADAM15 mRNA and sequence alignments between ADAM15 3′ UTR and hsa-miR-147b. (B) HUVECs were co-transfected with a miR mimic and pmirGlo/ADAM15 containing ADAM15 3′ UTR downstream of the luciferase reporter. Cells were analyzed for luciferase activity 48 h post-transfection. Data represent mean ± SEM. * P <0.05 vs. scrambled control.

Article Snippet: To examine the surface expression of ADAM15, transfected HUVECs were stained with anti-ADAM15 ectodomain antibody (Cat. # MAB935, R&D Systems, Minneapolis, MN, U.S.A.) for 30 min on ice followed by incubation with Cy3-conjugated secondary antibody (Cat. # 715-166-150, Jackson ImmunoResearch Laboratories, West Grove, PA, U.S.A.) for another 30 min.

Techniques: Sequencing, Transfection, Luciferase, Activity Assay, Control

Journal: PLoS ONE

Article Title: MicroRNA-147b Regulates Vascular Endothelial Barrier Function by Targeting ADAM15 Expression

doi: 10.1371/journal.pone.0110286

Figure Lengend Snippet: (A) Representative Western blot from HUVECs transfected with 200 nM miR-147b mimic or a scrambled miR control. (B) Quantitative densitometric analysis of ADAM15 expression at 48 h post-transfection. (C) Representative Western blot from HUVECs transfected with 200 nM miR-147b antagomir or a control antagomir. (D) Quantitative densitometric analysis of ADAM15 expression at 48 h post-transfection. Data represent mean ± SEM. * P <0.05 vs. scrambled control.

Article Snippet: To examine the surface expression of ADAM15, transfected HUVECs were stained with anti-ADAM15 ectodomain antibody (Cat. # MAB935, R&D Systems, Minneapolis, MN, U.S.A.) for 30 min on ice followed by incubation with Cy3-conjugated secondary antibody (Cat. # 715-166-150, Jackson ImmunoResearch Laboratories, West Grove, PA, U.S.A.) for another 30 min.

Techniques: Western Blot, Transfection, Control, Expressing

Journal: PLoS ONE

Article Title: MicroRNA-147b Regulates Vascular Endothelial Barrier Function by Targeting ADAM15 Expression

doi: 10.1371/journal.pone.0110286

Figure Lengend Snippet: Immunofluorescence labeling of ADAM15 in HUVECs transfected with scrambled miR (A), miR-147b mimic (B), scrambled miR and 200 ng/ml LPS (C), and miR-147b mimic and 200 ng/ml LPS (D). Green denotes ADAM15 staining, blue is DAPI staining of nuclei. Scale in (A) corresponds to 20 µm and applies to all images.

Article Snippet: To examine the surface expression of ADAM15, transfected HUVECs were stained with anti-ADAM15 ectodomain antibody (Cat. # MAB935, R&D Systems, Minneapolis, MN, U.S.A.) for 30 min on ice followed by incubation with Cy3-conjugated secondary antibody (Cat. # 715-166-150, Jackson ImmunoResearch Laboratories, West Grove, PA, U.S.A.) for another 30 min.

Techniques: Immunofluorescence, Labeling, Transfection, Staining

Journal: PLoS ONE

Article Title: MicroRNA-147b Regulates Vascular Endothelial Barrier Function by Targeting ADAM15 Expression

doi: 10.1371/journal.pone.0110286

Figure Lengend Snippet: At 48 h after transfection, live HUVECs were labeled with a monoclonal anti-ADAM15 ectodomain antibody and a secondary Cy3 conjugate. Cell surface expression was analyzed by flow cytometry (A–B). The bar graph shows quantitative cell surface ADAM15 expression in different treatment groups, each derived from 3 separate experiments (C). Data represent mean ± SEM. * P <0.05 vs. untreated control.

Article Snippet: To examine the surface expression of ADAM15, transfected HUVECs were stained with anti-ADAM15 ectodomain antibody (Cat. # MAB935, R&D Systems, Minneapolis, MN, U.S.A.) for 30 min on ice followed by incubation with Cy3-conjugated secondary antibody (Cat. # 715-166-150, Jackson ImmunoResearch Laboratories, West Grove, PA, U.S.A.) for another 30 min.

Techniques: Transfection, Labeling, Expressing, Flow Cytometry, Derivative Assay, Control

Journal: PLoS ONE

Article Title: MicroRNA-147b Regulates Vascular Endothelial Barrier Function by Targeting ADAM15 Expression

doi: 10.1371/journal.pone.0110286

Figure Lengend Snippet: (A) Representative Western blot from human lung microvascular endothelial cells (HLMEC) transfected with 200 nM miR-147b mimic or a miR negative control. (B) ADAM15 expression was measured 48 h post-transfection and quantified with densitometry. (C) Incubation with 200 ng/ml LPS for 24 h caused an increase in albumin permeability across HLMEC monolayers, an effect diminished in cells transfected with miR-147b. Data represent mean ± SEM. * P <0.05 vs. control scrambled miR, # P <0.05 vs. LPS scrambled miR.

Article Snippet: To examine the surface expression of ADAM15, transfected HUVECs were stained with anti-ADAM15 ectodomain antibody (Cat. # MAB935, R&D Systems, Minneapolis, MN, U.S.A.) for 30 min on ice followed by incubation with Cy3-conjugated secondary antibody (Cat. # 715-166-150, Jackson ImmunoResearch Laboratories, West Grove, PA, U.S.A.) for another 30 min.

Techniques: Western Blot, Transfection, Negative Control, Expressing, Incubation, Permeability, Control